Purpose This study aimed to assess the long-term risks associated with a history of infectious mononucleosis (IM), primarily caused by the Epstein-Barr virus (EBV). Specifically analyzing the potential increase in developing nasopharyngeal cancer (NPC) and lymphoma in patients with a history of IM and exploring the prevalence of other EBV-associated conditions.Materials and Methods The Korean National Health Insurance Service (NHIS) database was utilized for a retrospective analysis, covering data from 2002 to 2021. A total of 25,582 IM patients and controls were included, with 1:1 propensity score matching. The study monitored outcomes, including lymphoma, NPC, gastric cancer, multiple sclerosis, and all-cause mortality.Results Patients with a history of IM demonstrated a significantly higher incidence of lymphoma (hazard ratio [HR], 5.320; 95% confidence interval [CI], 3.208 to 8.820; p < 0.001) and NPC (HR, 7.116; 95% CI, 1.617 to 31.314; p=0.009) during the follow-up period compared with the control group. Additionally, the IM group showed an increased rate of all-cause mortality (HR, 2.225; 95% CI, 1.858 to 2.663; p < 0.001).Conclusion This study suggests that individuals with a history of IM have an elevated risk of developing lymphoma and NPC in South Korea, emphasizing the importance of vigilant follow-up and monitoring. The results advocate for heightened awareness and potential national monitoring policies to address the long-term health implications of EBV infection and to implement preventive measures.
Background and Objectives: We aimed to assess the efficacy of various treatments for patients experiencing sudden sensorineural hearing loss (SSNHL), with a focus on hyperbaric oxygen therapy (HBOT) and the effect of HBOT administration timing on hearing recovery.Subjects and Methods: In keeping with guideline recommendations, patients with SSNHL enrolled in this study received systemic corticosteroids, intratympanic dexamethasone, or HBOT in combination or as monotherapy. Hearing thresholds were determined using pure-tone audiometry (dB HL), and recovery was categorized as complete recovery (CR), partial recovery (PR), slight recovery (SR), or no recovery (NR). Post-treatment thresholds were assessed 2-3 months after symptom onset.Results: After treatment, we observed CR in 16 patients (15.2%), PR in 22 patients (21.0%), SR in 44 patients (42.0%), and NR in 23 patients (22.0%). Notably, among the 79 patients with severe hearing loss (>70 dB), those who received treatment within 2 weeks of onset showed better hearing outcomes than those who started treatment after 2 weeks. In the HBOT group, a shorter interval between symptom onset and HBOT initiation was associated with a higher likelihood of hearing improvement. Importantly, in patients with an initial hearing threshold of <70 dB, initiating HBOT within 2 weeks was associated with statistically significantly higher hearing recovery rates.Conclusions: The findings of our study support the premise that early initiation of HBOT within 2 weeks of symptom onset results in better hearing recovery in patients with SSNHL.
Intraosseous hemangiomas are rare benign vascular tumors that account for less than 1% of all bone tumors and are exceptionally uncommon in the sinonasal region. Their aggressive-appearing radiological features may mimic those of malignant bone tumors, creating diagnostic challenges. An 18-year-old man presented with right-sided nasal obstruction and epistaxis. Imaging revealed a large destructive mass in the right maxillary sinus that was suspicious for malignancy, including osteosarcoma. Endoscopic biopsy showed nonspecific benign osseous features that were discordant with the radiological findings. For this reason, endoscopic medial maxillectomy was performed. Histopathological examination with CD31 and CD34 immunostaining confirmed intraosseous venous hemangioma. Intraosseous hemangioma should be considered in the differential diagnosis of aggressive-appearing sinonasal masses, especially when imaging and biopsy findings are discordant, as its recognition may help prevent unnecessarily aggressive treatment.